Work

A Phase II Trial of Personalized Immunotherapy in Patients (pts) with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M HNSCC) That Have Progressed on Prior Immunotherapy.

Year: 2024

Type: article

Source: International Journal of Radiation Oncology*Biology*Physics

DOI: 10.1016/j.ijrobp.2024.01.019

Authors: D.P. Zandberg, J. Chen, C. Tatsuoka, D.P. Normolle, J. Ohr, B. Isett, Z. Rahman, M. Fenton, W. Gooding, L. Vujanovic, R. Bao, C. Marsh, D. Seastone, V. Gorantla, S. Pabla, J. Conroy, R.L. Ferris

Institutions: University of Pittsburgh, University of Pittsburgh Medical Center, UPMC Hillman Cancer Center, UPMC Health System, LabCorp (United States)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4392797774

FWCI: 0.307

Cites:

Cited by: 2

Related to: 10